Results 171 to 180 of about 4,367 (184)

Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection

Clinical Therapeutics, 2021
Yinuo Pang, Hoi-Kei Lon, Jasmina Kalabić   +2 more
exaly  

Risankizumab for pityriasis rubra pilaris

Clinical and Experimental Dermatology, 2021
E. Brocco, E. Laffitte
openaire   +2 more sources

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial

Journal of Dermatology, 2019
Mamitaro Ohtsuki, Atsuyuki Igarashi, Susumu Kitamura   +2 more
exaly  

Risankizumab for Crohn's disease

The Lancet, 2022
openaire   +2 more sources

Risankizumab

2020
Erica B. Lee, Deeti J. Pithadia, Kelly A. Reynolds, Jashin J. Wu   +3 more
openaire   +1 more source

Risankizumab/tacrolimus

Reactions Weekly, 2021
openaire   +1 more source

Risankizumab for the treatment of moderate to severe psoriasis

Expert Opinion on Biological Therapy, 2019
Corrado Blandizzi, Matteo Fornai, Marco Romanelli   +2 more
exaly  

Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study

Clinical Gastroenterology and Hepatology
Cyrielle Gilletta de Saint Joseph, Ludovic Caillo, Carmen Stefanescu   +2 more
exaly  

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies

Journal of Crohn's and Colitis
David T Rubin, Remo Panaccione, Marc Ferrante   +2 more
exaly  

Adalimumab/Risankizumab

Reactions Weekly
openaire   +2 more sources